Overview
2012Founded1
Compare with Silverback Therapeutics, Standard BioTools Inc. or Arcturus Therapeutics, or pick any stock.
- TickerNRIX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersDE1
- Websitewww.nurixtx.com
- Incorporated inDE4
- Business address1600 Sierra Point Pkwy, Brisbane, Ca 940054
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-340.2%Operating margin5
-314.9%Net margin5
54.0%Revenue growth, 20255
-49.1%Return on equity5
-$263.5MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Collaboration Revenue brought in 64% of the revenue Nurix (United States) broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Collaboration Revenue | $57.0M | $54.5M | $54.0M |
| License revenue | $20.0M | $0 | $30.0M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$316.9M
- Income tax0¢$760.0K
Out of $84.0M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-11-30 | 2024-11-30 | 2023-11-30 |
|---|---|---|---|
| Total revenue | $84.0M | $54.5M | $77.0M |
| Research and development | $316.9M | $221.6M | $189.1M |
| General and administrative | $52.7M | $45.9M | $42.9M |
| Total operating expenses | $369.6M | $267.6M | $232.1M |
| Loss from operations | -$285.7M | -$213.0M | -$155.1M |
| Interest and other income, net | $22.0M | $19.7M | $11.1M |
| Loss before income taxes | -$263.7M | -$193.3M | -$143.9M |
| Provision for income taxes | $760.0K | $270.0K | $0 |
| Net loss | -$264.5M | -$193.6M | -$143.9M |
| Net loss per share, basic (in USD per share) | -$3.05 | -$2.88 | -$2.65 |
| Net loss per share, diluted (in USD per share) | -$3.05 | -$2.88 | -$2.65 |
| Weighted-average number of shares outstanding, basic (in shares) | 86.7M shares | 67.1M shares | 54.3M shares |
| Weighted-average number of shares outstanding, diluted (in shares) | 86.7M shares | 67.1M shares | 54.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $247.0M | $110.0M | $54.6M | |
| Marketable securities | $346.0M | $499.6M | ||
| Prepaid expenses and other current assets | $13.9M | $9.8M | ||
| Total current assets | $606.8M | $619.4M | ||
| Operating lease right-of-use assets | $50.5M | $28.1M | ||
| Property and equipment, net | $22.5M | $17.8M | ||
| Restricted cash | $968.0K | $901.0K | $901.0K | |
| Other assets | $7.3M | $3.2M | ||
| Total assets | $688.1M | $669.3M | ||
| Accounts payable | $11.2M | $11.5M | ||
| Accrued expenses and other current liabilities | $54.9M | $38.0M | ||
| Operating lease liabilities, current | $2.8M | $8.0M | ||
| Deferred revenue, current | $17.6M | $38.4M | ||
| Total current liabilities | $86.5M | $95.9M | ||
| Operating lease liabilities, net of current portion | $52.9M | $20.3M | ||
| Deferred revenue, net of current portion | $10.0M | $26.2M | ||
| Total liabilities | $149.4M | $142.3M | ||
| Preferred stock, $0.001 par value 10,000,000 shares authorized as of November 30, 2025 and 2024; no shares issued and outstanding as of November 30, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value 500,000,000 shares authorized as of November 30, 2025 and 2024; 101,807,484 and 75,870,718 shares issued and outstanding as of November 30, 2025 and 2024, respectively | $102.0K | $76.0K | ||
| Additional paid-in capital | $1.5B | $1.3B | ||
| Accumulated other comprehensive income | $105.0K | $150.0K | ||
| Accumulated deficit | -$1.0B | -$738.8M | ||
| Total stockholders equity | $538.7M | $527.0M | $200.5M | $303.7M |
| Total liabilities and stockholders equity | $688.1M | $669.3M | ||
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 101.8M shares | 75.9M shares | ||
| Common stock, shares outstanding (in shares) | 101.8M shares | 75.9M shares |
| Period ending | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $247.0M | $110.0M | $54.6M | |
| Marketable securities | $346.0M | $499.6M | ||
| Prepaid expenses and other current assets | $13.9M | $9.8M | ||
| Total current assets | $606.8M | $619.4M | ||
| Operating lease right-of-use assets | $50.5M | $28.1M | ||
| Property and equipment, net | $22.5M | $17.8M | ||
| Restricted cash | $968.0K | $901.0K | $901.0K | |
| Other assets | $7.3M | $3.2M | ||
| Total assets | $688.1M | $669.3M | ||
| Accounts payable | $11.2M | $11.5M | ||
| Accrued expenses and other current liabilities | $54.9M | $38.0M | ||
| Operating lease liabilities, current | $2.8M | $8.0M | ||
| Deferred revenue, current | $17.6M | $38.4M | ||
| Total current liabilities | $86.5M | $95.9M | ||
| Operating lease liabilities, net of current portion | $52.9M | $20.3M | ||
| Deferred revenue, net of current portion | $10.0M | $26.2M | ||
| Total liabilities | $149.4M | $142.3M | ||
| Preferred stock, $0.001 par value 10,000,000 shares authorized as of November 30, 2025 and 2024; no shares issued and outstanding as of November 30, 2025 and 2024 | $0 | $0 | ||
| Common stock, $0.001 par value 500,000,000 shares authorized as of November 30, 2025 and 2024; 101,807,484 and 75,870,718 shares issued and outstanding as of November 30, 2025 and 2024, respectively | $102.0K | $76.0K | ||
| Additional paid-in capital | $1.5B | $1.3B | ||
| Accumulated other comprehensive income | $105.0K | $150.0K | ||
| Accumulated deficit | -$1.0B | -$738.8M | ||
| Total stockholders equity | $538.7M | $527.0M | $200.5M | $303.7M |
| Total liabilities and stockholders equity | $688.1M | $669.3M | ||
| Preferred stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 101.8M shares | 75.9M shares | ||
| Common stock, shares outstanding (in shares) | 101.8M shares | 75.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-11-30 | 2024-11-30 | 2023-11-30 |
|---|---|---|---|
| Net loss | -$264.5M | -$193.6M | -$143.9M |
| Depreciation and amortization | $8.7M | $9.3M | $7.5M |
| Stock-based compensation | $38.0M | $33.9M | $33.7M |
| Net accretion of discount on marketable securities | -$10.3M | -$11.3M | -$5.4M |
| Loss on disposal of property and equipment | $89.0K | $31.0K | $556.0K |
| Amortization of operating lease right-of-use assets | $10.1M | $7.1M | $6.1M |
| Other | $0 | $286.0K | $0 |
| Prepaid expenses and other assets | -$6.2M | -$459.0K | $2.1M |
| Accounts payable | -$630.0K | $5.2M | $1.6M |
| Deferred revenue | -$37.0M | -$28.5M | $19.5M |
| Operating lease liabilities | -$5.1M | -$6.4M | -$6.3M |
| Accrued expenses and other current liabilities | $17.3M | $11.8M | $3.1M |
| Net cash used in operating activities | -$249.5M | -$172.6M | -$81.4M |
| Purchases of marketable securities | -$455.7M | -$708.0M | -$246.3M |
| Maturities of marketable securities | $617.5M | $459.5M | $323.0M |
| Purchases of property and equipment | -$14.0M | -$9.3M | -$8.4M |
| Net cash provided by (used in) investing activities | $147.9M | -$257.7M | $68.3M |
| Proceeds from issuances of common stock and pre-funded warrants, net of issuance costs | $234.8M | $188.7M | $0 |
| Proceeds from exercise of stock options and pre-funded warrants | $1.7M | $5.1M | $988.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $2.2M | $2.1M | $2.2M |
| "Proceeds from issuances of common stock in ""at the market"" financing, net of issuance costs" | $0 | $289.8M | $0 |
| Repurchase of unvested early exercised stock options | $0 | -$15.0K | $0 |
| Net cash provided by financing activities | $238.6M | $485.7M | $3.2M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $137.0M | $55.4M | -$9.8M |
| Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities | $1.2M | $1.6M | $632.0K |
| Right-of-use assets recognized in exchange for lease obligations | $32.5M | $4.1M | $24.0M |
| Capitalized stock-based compensation related to internal-use software development | $20.0K | $14.0K | $74.0K |
| Issuance costs related to equity financing included in accrued expenses and other current liabilities | $371.0K | $0 | $0 |
| Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities | $0 | $117.0K | $0 |
| "Deferred issuance costs recognized related to the ""at the market"" financing" | $0 | $394.0K | $0 |
| Vesting of early exercised stock options | $0 | $33.0K | $117.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Nurix (United States), and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerArthur T. Sands Jul 23, 2020 to now13
- PresidentArthur T. Sands Jul 23, 2020 to now13
- Chief financial officerHoute Hans Van Jul 23, 2020 to now14
- Chief operating officerStefani Wolff Aug 17, 2021 to May 2, 202315
Board members and other officers (19)
- Chief Scientific OfficerGwenn M Hansen Jul 23, 2020 to now16
- Chief Business OfficerPierre Beaurang Jul 23, 2020 to Aug 11, 202117
- Board memberRoy D. Baynes Mar 13, 2025 to now18
- Board memberRoger D. Dansey Nov 10, 2025 to now19
- Board memberAnil Kapur Oct 16, 2024 to now20
- Board memberEdward C. Saltzman Sep 14, 2022 to now21
- Board memberClay B. Siegall Jun 1, 2021 to May 6, 202222
- Board memberJudith A. Reinsdorf Oct 1, 2021 to now23
- Board memberPaul M. Silva Oct 1, 2021 to now24
- Board memberArthur T. Sands Jul 23, 2020 to now13
- Board memberDavid L. Lacey Jul 23, 2020 to now25
- Board memberJeffrey K. Tong Jul 23, 2020 to May 24, 202126
- Board memberJulia P. Gregory Jul 23, 2020 to now27
- Board memberLeon Chen Jul 23, 2020 to May 24, 202128
- Board memberLori Anne Kunkel Jul 23, 2020 to now29
- Board memberRobert Tjian Jul 23, 2020 to Jul 29, 202030
- Board memberDavid Goeddel V. Jul 29, 2020 to Jul 29, 202031
- Board memberGwenn M Hansen Jul 1, 2017 to Feb 1, 20181
- General counselChristine Ring Jul 23, 2020 to now32
Former names
- Nurix, Inc.May 15, 2012 to Sep 18, 20154
Timeline
Filings
420 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 66 major events, 196 insider forms, 60 large holders, 77 other. The latest 20:
- Oct 15, 20264 EDGAR
- Oct 14, 2026144 EDGAR
- Oct 14, 20264 EDGAR
- Oct 13, 202610-Q EDGAR
- Oct 13, 20268-K EDGAR
- Oct 2, 2026144 EDGAR
- Oct 2, 20264 EDGAR
- Sep 23, 2026SCHEDULE 13G EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 20264 EDGAR
- Sep 1, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 5, 2026144 EDGAR
- Aug 5, 20264 EDGAR
- Aug 5, 20264 EDGAR
- Aug 4, 2026144 EDGAR
The 420 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 60 such filings since October 2021, the latest 10:
- Sep 23, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 2026SCHEDULE 13G
- Jul 31, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- May 6, 2026SCHEDULE 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 8,770,349 | $212.8M | 0.0% | −155,293 |
| Vestal Point Capital, LP | 8,050,000 | $195.3M | 4.6% | +1,550,000 |
| Deep Track Capital, LP | 7,736,455 | $187.7M | 2.8% | +1,391,211 |
| Rubric Capital Management LP | 7,227,778 | $175.3M | 1.6% | +4,753,893 |
| Fmr LLC | 5,485,215 | $133.1M | 0.0% | −56,056 |
| Morgan Stanley | 4,762,484 | $115.5M | 0.0% | −169,515 |
| State Street Corp | 4,677,244 | $113.5M | 0.0% | −463,951 |
| Baker Bros. Advisors LP | 4,658,556 | $113.0M | 0.6% | No change |
| Vanguard Capital Management LLC | 4,495,529 | $109.1M | 0.0% | +68,417 |
| Perceptive Advisors LLC | 4,320,422 | $104.8M | 1.6% | +609,545 |
| Redmile Group, LLC | 4,073,787 | $98.8M | 6.6% | −3,659,021 |
| General Atlantic, L.P. | 3,032,185 | $73.6M | 2.5% | −1,069,680 |
| Geode Capital Management, LLC | 2,537,291 | $61.6M | 0.0% | +17,062 |
| Pictet Asset Management Holding SA | 2,351,232 | $57.0M | 0.1% | −374,906 |
| ARK Investment Management LLC | 1,793,196 | $43.5M | 0.3% | +72,061 |
| Capital World Investors | 1,787,916 | $43.4M | 0.0% | +894,589 |
| Trails Edge Capital Partners, LP | 1,573,220 | $38.2M | 6.1% | −170,000 |
| Vanguard Portfolio Management LLC | 1,482,861 | $36.0M | 0.0% | +380,595 |
| Citadel Advisors LLC | 1,477,019 | $35.8M | 0.0% | +133,319 |
| Soleus Capital Management, L.P. | 1,465,163 | $35.5M | 1.2% | +527,000 |
| Dimensional Fund Advisors LP | 1,431,317 | $34.7M | 0.0% | +650,621 |
| Eventide Asset Management, LLC | 1,297,893 | $31.5M | 0.4% | No change |
| Braidwell LP | 1,286,769 | $31.2M | 1.2% | −463,997 |
| Kynam Capital Management, LP | 1,194,757 | $29.0M | 1.6% | No change |
| Woodline Partners LP | 1,064,006 | $25.8M | 0.1% | +138,562 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.nurixtx.com1
- WikidataQ106411724
- SEC EDGARCIK 1549595
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteNurix (United States) logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARRoy D. Baynes, Board member
- 19SEC EDGARRoger D. Dansey, Board member
- 20SEC EDGARAnil Kapur, Board member
- 21SEC EDGAREdward C. Saltzman, Board member
- 22SEC EDGARClay B. Siegall, Board member
- 23SEC EDGARJudith A. Reinsdorf, Board member
- 24SEC EDGARPaul M. Silva, Board member
- 25SEC EDGARDavid L. Lacey, Board member
- 26SEC EDGARJeffrey K. Tong, Board member
- 27SEC EDGARJulia P. Gregory, Board member
- 28SEC EDGARLeon Chen, Board member
- 29SEC EDGARLori Anne Kunkel, Board member
- 30SEC EDGARRobert Tjian, Board member
- 31SEC EDGARDavid Goeddel V., Board member
- 32SEC EDGARChristine Ring, General counsel